1-5 of 5
Joerg Thomalla
Close
Sort by
Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Britta Besemer, Mathias Haenel, Kaya Miah, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Andreas Neubauer, Christof Scheid, Roland Schroers, Ivana v. Metzler, Aneta Schieferdecker, Joerg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe M. Martens, Christian Kunz, Manfred Hensel, Andrea Seidel-Glaetzer, Katja Weisel, Marc-Steffen Raab, Hans Salwender
Journal: Blood
Blood (2021) 138 (Supplement 1): 486.
https://doi.org/10.1182/blood-2021-147323
Published: 2021
Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Hartmut Goldschmidt, Elias K Mai, Eva Nievergall, Roland Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana v. Metzler, Mathias Haenel, Christoph Mann, Anne-Marie Asemissen, Bernhard Heilmeier, Stefanie Huhn, Katharina Kriegsmann, Niels Weinhold, Steffen P. Luntz, Tobias A. W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Cyrus Khandanpour, Wolfgang Knauf, Markus Munder, Thomas Geer, Hendrik Riesenberg, Joerg Thomalla, Martin Hoffmann, Marc-Steffen Raab, Hans Salwender, Katja Weisel
Journal: Blood
Blood (2021) 138 (Supplement 1): 463.
https://doi.org/10.1182/blood-2021-145097
Published: 2021
Journal Articles

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Rudolf Weide, MD, Georg Hess, MD, Hubert Koeppler, MD, Jochen Heymanns, MD, Joerg Thomalla, MD, Ali Aldaoud, MD, Christoph Losem, MD, Stefan Schmitz, MD, Ursula Haak, MD, Christoph Huber, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin Dreyling, MD
Journal: Blood
Blood (2006) 108 (11): 2480.
https://doi.org/10.1182/blood.V108.11.2480.2480
Published: 2006
Journal Articles

Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group ( GLSG ).

Rudolf Weide, Hubert Koeppler, Jochen Heymanns, Joerg Thomalla, Georg Hess, Heinhold Gamm, Ali Aldaoud, Stephan Schmitz, Ursula Haak, Dirk Plewe, Oswald Burkhard, Bernd Gaede, Fokke Hinrichs, Karl-Heinz Pflueger, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood
Blood (2004) 104 (11): 2482.
https://doi.org/10.1182/blood.V104.11.2482.2482
Published: 2004
Journal Articles

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

Clinical Trials & Observations
Walter Fiedler, Rolf Mesters, Heike Tinnefeld, Sonja Loges, Peter Staib, Ulrich Dührsen, Michael Flasshove, Oliver G. Ottmann, Wolfram Jung, Franco Cavalli, Rolf Kuse, Joerg Thomalla, Hubert Serve, Anne M. O'Farrell, Mark Jacobs, Nicoletta M. Brega, Paul Scigalla, Dieter K. Hossfeld, Wolfgang E. Berdel
Journal: Blood
Blood (2003) 102 (8): 2763–2767.
https://doi.org/10.1182/blood-2002-10-2998
Published: 2003